Episode 43: Put It in Reverse Terry! Fixed-Dosed Kcentra for Vitamin K Antagonist Reversal

Share:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email
Photo of Jimmy Pruitt
Fixed-dose-Kcentra-Pharmacy-Friday_jlp2

References

  1. Kcentra (prothrombin complex concentrate [Human]) [package insert]. Kankakee, IL: CSL Behring LLC; 2013.
  2. Tomaselli, Gordon F., et al. “2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.” Journal of the American College of Cardiology 70.24 (2017): 3042-3067.
  3. Schwebach, Alyson A., Ryan A. Waybright, and Thomas J. Johnson. “A Review of Fixed‐Dose Four‐Factor Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal: Does One Dose Fit All?.” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy (2019).
  4. Khorsand, Nakisa, et al. “An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies.” haematologica 97.10 (2012): 1501-1506.
  5. Abdoellakhan, Rahat Amadkhan, et al. “Fixed versus variable dosing of prothrombin complex concentrate in vitamin K antagonist-related intracranial hemorrhage: a retrospective analysis.” Neurocritical care 26.1 (2017): 64-69.
  6. Klein L, Peters J, Miner J, Gorlin J. Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal. Am J Emerg Med. 2015;33(9):1213-1218.
  7. Astrup G, Sarangarm P, Burnett A. Fixed dose 4-factor prothrombin complex concentrate for the emergent reversal of warfarin: a retrospective analysis. J Thromb Thrombolysis. 2018;45(2):300-305.
  8. Dietrich, Mixon, Holowatyj et al. Multi-centered evaluation of a novel fixed-dose four-factor prothrombin complex concentrate protocol for warfarin reversal. Am J Emerg Med. 2020;38(10):2096-2100.
  9. Stoecker, Van Amber, Woster et al. Evaluation of fixed versus variable dosing of 4-factor prothrombin complex concentrate for emergent warfarin reversal. Am J Emerg Med. 2021;48:282-287.
  10. McMahon, Halfpap, Zhao et al. Evaluation of a fixed-dose regimen of 4-factor prothrombin complex concentrate for warfarin reversal. Ann Pharmacother. 2021. [Epub ahead of print]
  11. Elsamadisi P, Cepeda MAG, Yankama T, Wong A, Tran Q, Eche IM. Weight-Based Dosing Versus a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate in Obese Patients Requiring Vitamin K Antagonist Reversal. Am J Cardiovasc Drugs. 2021 May;21(3):355-361. doi: 10.1007/s40256-020-00442-w. Epub 2020 Nov 5. PMID: 33150496.
  12. Mohammadi, Yaribash, Mohmood, Talasaz. Efficacy and safety of the fixed-dose versus variable-dose of 4-PCC for vitakmin K antagonist reversal: a comprehensive systematic review  and meta-analysis. Cardiovasc Drug Ther. 2021. [Epub ahead of print]
  13. Dietrich SK, Mixon MA, Rech MA. Fixed-dose prothrombin complex concentrate for emergent warfarin reversal among patients with intracranial hemorrhage. Am J Emerg Med. 2021 Jun 26;49:326-330. doi: 10.1016/j.ajem.2021.06.032. Epub ahead of print. PMID: 34224954.

ABOUT AUTHOR

Jimmy L. Pruitt III, PharmD, BCPS, BCCCP

The Pharm So Hard Podcast is a show focused primarily on emergency medicine and hospital pharmacy related topics. To empower healthcare providers with the knowledge and skills they need to provide evidence-based, safe care for critically ill patients.

Posted On

By

Categories

Share

Share on facebook
Share on twitter
Share on linkedin

Subscribe to our Newsletter

New Episodes on 1st, 2nd, 4th Tuedays

Stay Connected to Get The Latest Podcast Alerts

Want to learn more?

Pharmacy and Acute Care University

An e-learning platform that empowers healthcare providers with knowledge and skills so they can provide evidence-based, safe care for these types of patients.

Pin It on Pinterest

%d bloggers like this: